• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $COR

    Cencora Inc.

    Subscribe to $COR
    $COR
    Other Pharmaceuticals
    Health Care

    CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options — all of which leads to a best-in-class customer experience and lasting relationships.

    IPO Year:

    Exchange: NYSE

    Website: CoreSite.com

    Peers

    $EQIX
    $DLR

    Recent Analyst Ratings for Cencora Inc.

    DatePrice TargetRatingAnalyst
    12/4/2024$280.00Outperform
    Mizuho
    9/18/2024$275.00 → $245.00Buy → Neutral
    BofA Securities
    2/26/2024$261.00Outperform
    Leerink Partners
    1/3/2024$242.00Overweight
    Barclays
    12/14/2023$213.00Equal Weight
    Wells Fargo
    12/14/2021$162.00 → $170.00Buy → Neutral
    Citigroup
    11/26/2021$136.00 → $170.00Sector Perform
    RBC Capital
    11/16/2021Underweight → Equal-Weight
    Barclays
    11/16/2021$158.00 → $170.00Outperform → Neutral
    Credit Suisse
    11/16/2021Outperform → Market Perform
    Raymond James
    See more ratings

    Cencora Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Nally Dennis M was granted 121 shares, increasing direct ownership by 0.92% to 13,251 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      5/5/25 4:07:07 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Director Baumann Werner was granted 125 shares, increasing direct ownership by 5% to 2,896 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      5/5/25 4:05:32 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Director Tyler Lauren M was granted 104 shares, increasing direct ownership by 4% to 2,875 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      5/5/25 4:03:54 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Chief Financial Officer Cleary James F disposed of 35,000 shares, decreasing direct ownership by 23% to 114,293 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      4/25/25 4:32:25 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Executive Chairman Collis Steven H exercised 12,579 shares at a strike of $86.09 and sold $4,108,508 worth of shares (14,579 units at $281.81), decreasing direct ownership by 0.63% to 315,913 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      4/23/25 4:24:48 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • President & CEO Mauch Robert P. exercised 3,225 shares at a strike of $86.09 and sold $1,437,681 worth of shares (4,969 units at $289.33), decreasing direct ownership by 4% to 47,582 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      4/22/25 4:06:45 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Executive Chairman Collis Steven H exercised 12,578 shares at a strike of $86.09 and sold $3,928,917 worth of shares (14,578 units at $269.51), decreasing direct ownership by 0.63% to 317,913 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      3/26/25 4:40:13 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Executive Vice President Campbell Elizabeth S sold $1,107,192 worth of shares (4,127 units at $268.28), decreasing direct ownership by 22% to 14,665 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      3/26/25 4:38:12 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • President & CEO Mauch Robert P. exercised 3,226 shares at a strike of $86.09 and sold $1,296,822 worth of shares (4,970 units at $260.93), decreasing direct ownership by 3% to 49,326 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      3/19/25 4:38:40 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • SVP & Chief Accounting Officer Krikorian Lazarus sold $520,120 worth of shares (2,000 units at $260.06), decreasing direct ownership by 9% to 20,154 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      3/11/25 4:07:51 PM ET
      $COR
      Other Pharmaceuticals
      Health Care

    Cencora Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Cencora Inc.

      10-Q - Cencora, Inc. (0001140859) (Filer)

      5/7/25 1:48:31 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Cencora, Inc. (0001140859) (Filer)

      5/7/25 6:36:20 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Cencora, Inc. (0001140859) (Filer)

      3/10/25 5:00:25 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Cencora, Inc. (0001140859) (Filer)

      3/10/25 6:30:49 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Cencora, Inc. (0001140859) (Filer)

      2/10/25 5:00:14 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • SEC Form 10-Q filed by Cencora Inc.

      10-Q - Cencora, Inc. (0001140859) (Filer)

      2/5/25 2:09:29 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Cencora, Inc. (0001140859) (Filer)

      2/5/25 6:34:05 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Cencora Inc.

      SCHEDULE 13G/A - Cencora, Inc. (0001140859) (Subject)

      1/31/25 3:59:35 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • SEC Form DEFA14A filed by Cencora Inc.

      DEFA14A - Cencora, Inc. (0001140859) (Filer)

      1/23/25 4:21:59 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • SEC Form DEF 14A filed by Cencora Inc.

      DEF 14A - Cencora, Inc. (0001140859) (Filer)

      1/23/25 4:17:31 PM ET
      $COR
      Other Pharmaceuticals
      Health Care

    Cencora Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Cencora Expands Enterprise Leadership Team with Two Senior Appointments

      Francois Mandeville Named Executive Vice President, Strategy and M&A Pawan Verma Appointed Executive Vice President, Chief Data and Information Officer Cencora, Inc. (NYSE:COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora's enterprise leadership team, bringing their extensive experience and expertise to help advance the company's pharmaceutical-centric strategy and drive growth for Cencora and its customers. "We're thrilled to welcome Francois and Pawan to Cencora's leadership team," said Bob Mauch, President and Chief Ex

      11/4/24 8:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Network Wireless Solutions (NWS) Appoints Michael Millegan to Board of Directors

      The communications industry veteran brings years of experience to NWS Network Wireless Solutions, LLC ("NWS"), a rapidly growing solutions and logistics provider to carriers and telecommunications contractors, announced today the appointment of Michael Millegan to its board. NWS is a portfolio company of Grain Management, LLC ("Grain"), a leading Washington, D.C.-based investment firm focused on the global communications sector. Mr. Millegan is a seasoned technology executive with several years of experience leading company strategy, including sales, marketing, supply chain operations, cell site build-out, and engineering. Currently, Mr. Millegan serves as an independent board director fo

      9/14/21 2:00:00 PM ET
      $AXS
      $COR
      $POR
      $WTT
      Property-Casualty Insurers
      Finance
      Other Pharmaceuticals
      Health Care

    Cencora Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Durcan Dermot Mark bought $109,290 worth of shares (500 units at $218.58), increasing direct ownership by 2% to 21,876 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      5/29/24 4:02:27 PM ET
      $COR
      Other Pharmaceuticals
      Health Care

    Cencora Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cencora Inc.

      SC 13G/A - Cencora, Inc. (0001140859) (Subject)

      11/14/24 1:22:34 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cencora Inc.

      SC 13D/A - Cencora, Inc. (0001140859) (Subject)

      8/5/24 6:43:49 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by CoreSite Realty Corporation (Amendment)

      SC 13G/A - CoreSite Realty Corp (0001490892) (Subject)

      7/12/21 8:29:18 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed

      SC 13G - CoreSite Realty Corp (0001490892) (Subject)

      2/11/21 3:13:43 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - CoreSite Realty Corp (0001490892) (Subject)

      2/10/21 10:46:48 AM ET
      $COR
      Other Pharmaceuticals
      Health Care

    Cencora Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho resumed coverage on Cencora with a new price target

      Mizuho resumed coverage of Cencora with a rating of Outperform and set a new price target of $280.00

      12/4/24 7:30:44 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora downgraded by BofA Securities with a new price target

      BofA Securities downgraded Cencora from Buy to Neutral and set a new price target of $245.00 from $275.00 previously

      9/18/24 8:27:47 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Leerink Partners initiated coverage on Cencora with a new price target

      Leerink Partners initiated coverage of Cencora with a rating of Outperform and set a new price target of $261.00

      2/26/24 7:28:01 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Barclays initiated coverage on Cencora with a new price target

      Barclays initiated coverage of Cencora with a rating of Overweight and set a new price target of $242.00

      1/3/24 7:43:42 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Wells Fargo initiated coverage on Cencora with a new price target

      Wells Fargo initiated coverage of Cencora with a rating of Equal Weight and set a new price target of $213.00

      12/14/23 6:54:24 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • CoreSite Realty downgraded by Citigroup with a new price target

      Citigroup downgraded CoreSite Realty from Buy to Neutral and set a new price target of $170.00 from $162.00 previously

      12/14/21 5:11:57 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • RBC Capital reiterated coverage on CoreSite Realty with a new price target

      RBC Capital reiterated coverage of CoreSite Realty with a rating of Sector Perform and set a new price target of $170.00 from $136.00 previously

      11/26/21 6:46:02 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • CoreSite Realty upgraded by Barclays

      Barclays upgraded CoreSite Realty from Underweight to Equal-Weight

      11/16/21 6:10:01 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • CoreSite Realty downgraded by Credit Suisse with a new price target

      Credit Suisse downgraded CoreSite Realty from Outperform to Neutral and set a new price target of $170.00 from $158.00 previously

      11/16/21 5:27:40 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • CoreSite Realty downgraded by Raymond James

      Raymond James downgraded CoreSite Realty from Outperform to Market Perform

      11/16/21 4:44:49 AM ET
      $COR
      Other Pharmaceuticals
      Health Care

    Cencora Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cencora Reports Fiscal 2025 Second Quarter Results

      Revenue of $75.5 billion for the Second Quarter, a 10.3 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $3.68 and Adjusted Diluted EPS of $4.42 Adjusted Diluted EPS Guidance Range Raised to $15.70 to $15.95 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described

      5/7/25 6:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call via

      3/28/25 7:00:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Announces Common Share Repurchase From Walgreens Boots Alliance

      Cencora, Inc. (NYSE:COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance's sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended. Cencora intends to repurchase shares from Walgreens Boots Alliance at the price per share equal to the price in the Rule 144 sale. The concurrent share repurchase will be made under Cencora's share repurchase program and the repurchased shares will be held in treasury. The sale of Cencora shares by Walgreens Boots Alliance is occurring simultaneously with the early set

      2/6/25 8:37:00 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

      Transaction Highlights Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional

      2/6/25 8:30:00 PM ET
      $COR
      $WBA
      Other Pharmaceuticals
      Health Care
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Cencora Reports Fiscal 2025 First Quarter Results

      Revenue of $81.5 billion for the First Quarter, a 12.8 Percent Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.50 and Adjusted Diluted EPS of $3.73 Adjusted Diluted EPS Guidance Range Raised to $15.25 to $15.55 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 first quarter ended December 31, 2024, revenue increased 12.8 percent year-over-year to $81.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.50 for the first quarter of fiscal 2025 compared to $2.98 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items descri

      2/5/25 6:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 5, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access t

      1/8/25 7:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Completes Acquisition of Retina Consultants of America

      Acquisition Advances Specialty Leadership Adjusted Diluted EPS Guidance Range Raised to $15.15 to $15.45 for Fiscal 2025 Cencora, Inc. (NYSE:COR) today announced the completion of its previously announced acquisition of Retina Consultants of America ("RCA"), a leading management services organization (MSO) of retina specialists. Cencora has acquired an interest in RCA of approximately 85%, with certain RCA physicians and members of the management team retaining a minority equity interest in the company. After giving effect to the equity rollover, a cash capitalization of RCA that Cencora has made, the payment of transaction fees and expenses and the repayment of debt, Cencora's cash o

      1/2/25 4:15:00 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Closes $1.8 Billion Senior Notes Offering

      Cencora, Inc. (NYSE:COR) today announced the closing of its public offering of $500,000,000 aggregate principal amount of its 4.625% Senior Notes due December 15, 2027 (the "2027 Notes"), $600,000,000 aggregate principal amount of its 4.850% Senior Notes due December 15, 2029 (the "2029 Notes") and $700,000,000 aggregate principal amount of its 5.150% Senior Notes due February 15, 2035 (the "2035 Notes" and, together with the 2027 Notes and the 2029 Notes, the "Notes"), in an underwritten registered public offering. The offering was made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the "SEC") on November 26, 2024. Cencora

      12/9/24 4:15:00 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Prices $500 Million 4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035

      Cencora, Inc. (NYSE:COR) today announced that it priced $500 million aggregate principal amount of its 4.625% Senior Notes due December 15, 2027 (the "2027 Notes"), $600 million aggregate principal amount of its 4.850% Senior Notes due December 15, 2029 (the "2029 Notes") and $700 million aggregate principal amount of its 5.150% Senior Notes due February 15, 2035 (the "2035 Notes" and, together with the 2027 Notes and the 2029 Notes, the "Notes"), in an underwritten registered public offering. The offering is being made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the "SEC") on November 26, 2024. The offering is expected to

      12/2/24 10:49:00 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results

      Revenue of $79.1 Billion for the Fourth Quarter, a 14.7 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $0.02 and Adjusted Diluted EPS of $3.34 Revenue of $294.0 Billion for Fiscal Year 2024, a 12.1 Percent Year-Over-Year Increase Fiscal Year 2024 GAAP Diluted EPS of $7.53 and Adjusted Diluted EPS of $13.76 Company increases its quarterly dividend by 8 percent Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 fourth quarter ended September 30, 2024, revenue increased 14.7 percent to $79.1 billion. Revenue increased 12.1 percent to $294.0 billion for the fiscal year. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earni

      11/6/24 6:35:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care

    Cencora Inc. Financials

    Live finance-specific insights

    See more
    • Cencora Reports Fiscal 2025 Second Quarter Results

      Revenue of $75.5 billion for the Second Quarter, a 10.3 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $3.68 and Adjusted Diluted EPS of $4.42 Adjusted Diluted EPS Guidance Range Raised to $15.70 to $15.95 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described

      5/7/25 6:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call via

      3/28/25 7:00:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

      Transaction Highlights Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional

      2/6/25 8:30:00 PM ET
      $COR
      $WBA
      Other Pharmaceuticals
      Health Care
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Cencora Reports Fiscal 2025 First Quarter Results

      Revenue of $81.5 billion for the First Quarter, a 12.8 Percent Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.50 and Adjusted Diluted EPS of $3.73 Adjusted Diluted EPS Guidance Range Raised to $15.25 to $15.55 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 first quarter ended December 31, 2024, revenue increased 12.8 percent year-over-year to $81.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.50 for the first quarter of fiscal 2025 compared to $2.98 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items descri

      2/5/25 6:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 5, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access t

      1/8/25 7:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results

      Revenue of $79.1 Billion for the Fourth Quarter, a 14.7 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $0.02 and Adjusted Diluted EPS of $3.34 Revenue of $294.0 Billion for Fiscal Year 2024, a 12.1 Percent Year-Over-Year Increase Fiscal Year 2024 GAAP Diluted EPS of $7.53 and Adjusted Diluted EPS of $13.76 Company increases its quarterly dividend by 8 percent Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 fourth quarter ended September 30, 2024, revenue increased 14.7 percent to $79.1 billion. Revenue increased 12.1 percent to $294.0 billion for the fiscal year. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earni

      11/6/24 6:35:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Announces Date and Time for Fourth Quarter Fiscal 2024 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2024 on Wednesday, November 6, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 6, 2024. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the

      10/1/24 7:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Reports Fiscal 2024 Third Quarter Results

      Revenue of $74.2 billion for the Third Quarter, a 10.9 Percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $2.42 and Adjusted Diluted EPS of $3.34 Adjusted Diluted EPS Guidance Range Raised to $13.55 to $13.65 for Fiscal 2024 Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 third quarter ended June 30, 2024, revenue increased 10.9 percent year-over-year to $74.2 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.42 for the third quarter of fiscal 2024 compared to $2.35 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items desc

      7/31/24 6:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Announces Date and Time for Third Quarter Fiscal 2024 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2024 on Wednesday, July 31, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on July 31, 2024. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer Robert P. Mauch, Executive Vice President & Chief Operating Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10

      7/5/24 4:15:00 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Reports Fiscal 2024 Second Quarter Results

      Revenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80 Adjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024 Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 second quarter ended March 31, 2024, revenue increased 7.8 percent year-over-year to $68.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items

      5/1/24 6:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care